Literature DB >> 18036561

Relation of ischemia-modified albumin levels and left ventricular systolic function in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.

Alberto Dominguez-Rodriguez1, Pedro Abreu-Gonzalez, Martín J Garcia-Gonzalez, Sima Samimi-Fard, Juan Carlos Kaski.   

Abstract

BACKGROUND: Ischemia-modified albumin (IMA) has been shown to be elevated in patients after percutaneous coronary intervention (PCI). Our goal was to investigate the association between IMA levels and left ventricular ejection fraction in patients with ST-segment elevation myocardial infarction (STEMI) treated with PCI and who developed heart failure during their Coronary Care Unit (CCU) stay.
METHODS: We assessed 75 patients with a first STEMI. Presence of heart failure was assessed during CCU admission, and patients were subdivided into 2 groups: group A (n=45) comprised patients in Killip class I, and group B (n=30) Killip classes>I. Serum IMA concentration was measured within the first 15 min post-PCI. The IMA measured was performed using an indirect method based in the Albumin Cobalt Binding (ACB) colorimetric assay. The ideal cutoff value of IMA was calculated by the receiver operating characteristic (ROC) curve analysis.
RESULTS: Serum IMA concentrations were significantly higher in group B than in group A (0.37+/-0.09 vs 0.30+/-0.06 (A.U.); p<0.0001). The sensitivity and specificity of IMA for heart failure were 93.3% and 37.7%, respectively, at 0.31 A.U. Multivariable adjustment IMA showed a significant inverse correlation with left ventricular ejection function (r=-0.32; p=0.004). On multivariable analysis both IMA (OR=2.1, 95%CI: 1.2 to 3.9, p<0.001) and left ventricular ejection function (OR=1.7, 95%CI: 1.1 to 2.1, p<0.01) correlated with the occurrence of heart failure.
CONCLUSION: In patients with STEMI undergoing PCI, serum IMA concentrations are significantly related to LVEF and represent an early marker of left ventricular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18036561     DOI: 10.1016/j.cca.2007.10.030

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

1.  Role of ischemia-modified albumin in estimating the extent and scope of cardiac ischemia in patients with ST elevation myocardial infarction.

Authors:  James Chek; Jaroslav Dusek; Josef Stasek; Jan Vojacek; Josef Bis; Martina Ulrychova; Milos Tichy; Tomas Tomko; Josef Bukac
Journal:  Heart Vessels       Date:  2011-01-26       Impact factor: 2.037

2.  Clinical significance of ischemia-modified albumin in the diagnosis of doxorubicin-induced myocardial injury in breast cancer patients.

Authors:  Yinghuan Ma; Wanjun Kang; Yongxin Bao; Fubin Jiao; Yiran Ma
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

3.  Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study.

Authors:  Yüksel Çavuşoğlu; Şule Korkmaz; Selda Demirtaş; Erkan Gencer; Hatice Şaşmaz; Fezan Mutlu; Hakan Güneş; Uğur Kadir Mert; Sedat Özdemir; Süleyman Kalaycı; Mehmet Birhan Yılmaz
Journal:  Anatol J Cardiol       Date:  2015-08       Impact factor: 1.596

4.  Role of ischemia-modified albumin in patients with acute decompensated heart failure.

Authors:  Defeng Pan; Dongye Li
Journal:  Anatol J Cardiol       Date:  2015-08       Impact factor: 1.596

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.